Cholecystokinin-8 vs Somatostatin
Head-to-head comparison of Cholecystokinin-8 (Cholecystokinin (sulfated C-terminal octapeptide, CCK-8)) and Somatostatin (Somatostatin-14) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Cholecystokinin-8 | Somatostatin |
|---|---|---|
| Category | Endocrine Peptides | Pain Management |
| Full Name | Cholecystokinin (sulfated C-terminal octapeptide, CCK-8) | Somatostatin-14 |
| Molecular Weight | 1143.2 Da | 1637.85 |
| Half-Life | 1-2 min | 1-3 min |
| Amino Acids | DY(SO3H)MGWMDF-NH2 | 14 |
| Typical Dose | physiologic low-picomolar-nanomolar range|research-dependent | N/A|N/A |
| Route | endogenous secretion|research IV/SC | IV/SC |
| Purity | ≥98% | ≥98% |
| Studies Count | 97 | 84 |
| Research Status | Endogenous | Approved |
Cholecystokinin-8 Benefits
- ✓gallbladder contraction
- ✓pancreatic enzyme release
- ✓satiety signaling
Somatostatin Benefits
- ✓nociceptive inhibition
- ✓anti-inflammatory signaling
- ✓visceral pain modulation
Cholecystokinin-8 Dosing
physiologic secretion|research-dependent
Somatostatin Dosing
N/A|N/A
Cholecystokinin-8 Side Effects
- ⚠abdominal cramping
- ⚠nausea
- ⚠biliary contraction
Somatostatin Side Effects
- ⚠hyperglycemia
- ⚠bradycardia
- ⚠GI upset
Research Overview
Cholecystokinin-8
CCK-8 is a canonical gut hormone fragment with extensive documentation in digestive physiology and appetite control. Sulfation of the tyrosine residue is important for high-affinity receptor activity.
Somatostatin
Somatostatin reduces release of multiple excitatory mediators and can suppress pain signaling in preclinical and limited translational work. Its analgesic use is not standard, but the peptide is real and mechanistically relevant to pain control.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.